Clinical trials recruiting for Pulmonary Arterial Hypertension (PAH)
20
Recruiting trials
14
US states with sites
17
Countries
5%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 2 |
| Colorado | 2 |
| Arizona | 1 |
| District of Columbia | 1 |
| Florida | 1 |
| Kansas | 1 |
| Maryland | 1 |
| Massachusetts | 1 |
| Michigan | 1 |
| Ohio | 1 |
| Oregon | 1 |
| Pennsylvania | 1 |
Top cities
Aurora, Colorado 2Ann Arbor, Michigan 1Bend, Oregon 1Bethesda, Maryland 1Boston, Massachusetts 1Columbus, Ohio 1Houston, Texas 1Jacksonville, Florida 1Kansas City, Kansas 1Philadelphia, Pennsylvania 1
Self-screener
Recruiting trials
- A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
- A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
- A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
- COMPERA / COMPERA-KIDS
- Comparison of Sequential to Initial Combination Therapy in PAH
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)
- Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
- PAH Exercise Study
- PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
- PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
- Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
- Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
- Study of Intravenous ZMA001 in Healthy Subjects
- Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
- The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
- Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
- imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Related conditions
Trials recruiting for Pulmonary Arterial Hypertension (PAH) often also study these conditions. Each links to its own recruiting-trial list.
Hypertension 1201Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) 7Pulmonary arterial hypertension 49Pulmonary Vascular Disease 5Systemic Sclerosis (SSc) 28Pulmonary Hypertension (PH) 3Pulmonary hypertension 95Exercise Therapy 5Comorbidities 3Cardiovascular Disease (CVD) 3
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pulmonary Arterial Hypertension (PAH) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.